EyePoint

Get the latest jobs and industry news

Based on strong Phase 2 data showing early and sustained disease control with just one dose, we’re advancing a novel mechanism of action with the goal to transform retinal disease treatment.

The first and only investigational sustained release TKI advancing through the clinic in wet AMD and DME, the two largest retinal disease markets with significant need for more durable treatments.

Supported by robust safety and efficacy data, our investigational TKI for retinal disease is advancing with the potential to transform the treatment paradigm. Investigational sustained release TKI designed for: ✅ Continuous, steady dosing for at least 6 months ✅ Sustained release of entire drug before bioerosion ✅ Standard in-office intravitreal injection ✅ No PEG, no PLGA, no free-floating drug particles

Backed by robust Phase 2 data showing nearly 2 out of 3 patients were supplement-free for 6 months after just one dose. #ICYMI - Our pivotal Phase 3 program is on track to share topline data in mid-2026.